Finance

Lists
EW:NYSE
Edwards Lifesciences Corp
83,53 US$
-0,89%
(-0,75) 1D
9 ოქტ, 11:42:54 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EW...
Open
84,60 US$
High
85,34 US$
Low
83,22 US$
Mkt. cap
48,15 მლრდ.
Avg. vol.
3,43 მლნ.
Volume
713,62 ათ.
P/E ratio
48,33
52-wk high
96,29 US$
52-wk low
72,30 US$
EPS
1,73 US$
Beta
0,87
Shares outstanding
576,40 მლნ.
No. of employees
16 ათ.
Open
84,60 US$
High
85,34 US$
Low
83,22 US$
Mkt. cap
48,15 მლრდ.
Avg. vol.
3,43 მლნ.
Volume
713,62 ათ.
P/E ratio
48,33
52-wk high
96,29 US$
52-wk low
72,30 US$
EPS
1,73 US$
Beta
0,87
Shares outstanding
576,40 მლნ.
No. of employees
16 ათ.
News stories
From web sources and news partners
Investing.com Nigeria
Investing.com Nigeria
·
10 საათის წინ
Form 4 Edwards Lifesciences Corp For: 9 October By Investing.com
Investing.com
Investing.com
·
10 საათის წინ
Edwards Lifesciences CVP Daniel Lippis sells $53k in stock
Profile
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027. Wikipedia
About Edwards Lifesciences Corp
CEO-
Employees16 ათ.
Founded1958
Headquartersირვაინი, კალიფორნია, ამერიკის შეერთებული შტატები
SectorMedical device
Analyst ratings
Based on 16 analysts giving stock ratings to EW in the past 3 months
Strong buy
Buy
13
Hold
3
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for EW in the last 3 months.
Highest
Current 83,53 US$
110,00 US$ (+31,69%)
Average
104,00 US$ (+24,51%)
Lowest
85,00 US$ (+1,76%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Wood
UBS
Buy
Maintained
110,00 US$
+31,7%
10/07/2026
Matt Miksic
Barclays
Buy
Maintained
110,00 US$
+31,7%
10/07/2026
Tycho Peterson
Jefferies
Buy
Initiated
110,00 US$
+31,7%
10/07/2026
Joanne Wuensch
Citi
Buy
Maintained
110,00 US$
+31,7%
10/05/2026
Kendall Au
RBC Capital
Buy
Maintained
110,00 US$
+31,7%
10/01/2026
Mike Kratky
Leerink Partners
Buy
Reiterated
101,00 US$
+20,9%
09/28/2026
Adam Maeder
Piper Sandler
Buy
Maintained
101,00 US$
+20,9%
09/21/2026
Matthew Taylor
Jefferies
Buy
Maintained
105,00 US$
+25,7%
09/11/2026
Marie Thibault
BTIG
Buy
Maintained
110,00 US$
+31,7%
09/10/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
09/10/2026
William Plovanic
Canaccord Genuity
Hold
Maintained
85,00 US$
+1,8%
08/03/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
105,00 US$
+25,7%
07/28/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
110,00 US$
+31,7%
07/24/2026
Suraj Kalia
Oppenheimer
Hold
Maintained
-
-
07/24/2026
Richard Newitter
Truist Financial
Hold
Reiterated
95,00 US$
+13,7%
07/24/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
110,00 US$
+31,7%
07/23/2026
Travis Steed
Bank of America Securities
Buy
Maintained
100,00 US$
+19,7%
07/21/2026
Josh Jennings
TD Cowen
Buy
Reiterated
104,00 US$
+24,5%
07/23/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
105,00 US$
+25,7%
07/15/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
100,00 US$
+19,7%
07/06/2026
David Roman
Goldman Sachs
Buy
Maintained
98,00 US$
+17,3%
06/15/2026
Krish Sankar
TD Cowen
Buy
Reiterated
104,00 US$
+24,5%
06/02/2026
David Toung
Argus Research
Buy
Maintained
-
-
05/21/2026
David Rescott
Robert W. Baird
Hold
Maintained
87,00 US$
+4,2%
04/24/2026
Michael Polark
Wolfe Research
Buy
Upgraded
92,00 US$
+10,1%
04/01/2026
Danielle Antalffy
UBS
Hold
Maintained
90,00 US$
+7,7%
02/12/2026
Larry Biegelsen
Wells Fargo
Buy
Reiterated
100,00 US$
+19,7%
02/11/2026
Last report
23 ივლ. 2026
Fiscal period
Q2 2026
0,78 US$ / 0,74 US$
+5,11%beat
Revenue / Est. (USD)
1,74 მლრდ. / 1,70 მლრდ.
+2,44%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
1,55 მლრდ.
1,57 მლრდ.
1,65 მლრდ.
1,74 მლრდ.
Cost of goods sold
345,20 მლნ.
343,00 მლნ.
362,60 მლნ.
392,40 მლნ.
Cost of revenue
345,20 მლნ.
343,00 მლნ.
362,60 მლნ.
392,40 მლნ.
Research and development expenses
280,70 მლნ.
267,70 მლნ.
263,30 მლნ.
278,90 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
514,60 მლნ.
601,20 მლნ.
522,20 მლნ.
561,20 მლნ.
Operating expense
782,80 მლნ.
854,60 მლნ.
771,30 მლნ.
829,10 მლნ.
Total operating expenses
1,13 მლრდ.
1,20 მლრდ.
1,13 მლრდ.
1,22 მლრდ.
Operating income
425,10 მლნ.
372,00 მლნ.
514,70 მლნ.
519,50 მლნ.
Other non operating income
1,10 მლნ.
2,30 მლნ.
69,90 მლნ.
-25,00 მლნ.
EBT including unusual items
348,40 მლნ.
90,40 მლნ.
459,00 მლნ.
519,80 მლნ.
EBT excluding unusual items
444,50 მლნ.
464,00 მლნ.
603,60 მლნ.
511,10 მლნ.
Income tax expense
56,10 მლნ.
26,20 მლნ.
78,30 მლნ.
278,40 მლნ.
Effective tax rate
16,10%
28,98%
17,06%
53,56%
Other operating expenses
-12,50 მლნ.
-14,30 მლნ.
-14,20 მლნ.
-11,00 მლნ.
Net income
291,10 მლნ.
91,20 მლნ.
380,70 მლნ.
241,90 მლნ.
Net profit margin
18,74%
5,81%
23,09%
13,89%
Earnings per share
0,67
0,58
0,78
0,78
Interest and investment income
16,70 მლნ.
114,20 მლნ.
17,40 მლნ.
15,00 მლნ.
Interest expense
-
-20,40 მლნ.
-
-
Net interest expenses
16,70 მლნ.
93,80 მლნ.
17,40 მლნ.
15,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
464,30 მლნ.
414,70 მლნ.
555,60 მლნ.
562,20 მლნ.
Gain or loss from assets sale
-
-33,90 მლნ.
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები